Journal of Stem Cell Research & Therapy

The influence of TIMP-2 gene expression on melanoma cell metastasis

4^th International Conference and Exhibition on Cell & Gene Therapy

August 10-12, 2015 London, UK

Emilia Grecka1, Malgorzata Statkiewicz1, Michal Mikula1, Agnieszka Gorska2 and Maciej Malecki2

Posters-Accepted Abstracts: J Stem Cell Res Ther

Abstract:

Melanoma is one of the most malignant human cancers with the rapidly rising number of cases worldwide. Due to the low
effectiveness of the advanced melanoma treatment with available methods as well as high mortality mainly caused by
metastasis, there is urgent need for new therapeutic strategies in advanced melanoma. Tissue inhibitor of metalloproteinases
2 (TIMP-2) has an inhibitory effect on tumour growth, angiogenesis, tumour invasiveness and metastasis in a mechanism
likely independent of metalloproteinases activity. Despite the fact, that TIMP-2 is considered as a metastasis suppressor gene,
it remains unknown in what mechanism this protein influences metastasis process of melanoma. We determined the impact
of TIMP-2 overexpression in melanoma cells allografts in vivo. Murine B16-F10 melanoma cells overexpressing TIMP-2 were
grafted into mice by subcutaneous or tail vein injections in order to examine tumour growth rate and metastatic potential
respectively. mRNA levels of selected metastasis related genes in in vitro cultured cells were measured with RT-qPCR. Our data
demonstrated that B16-F10/TIMP-2 subcutaneous tumors had slower growth rate and cells injected to bloodstream did not
metastase to lungs. TIMP-2 overexpression modulated the mRNA expression of genes belonging to Nf-kb signaling pathway,
interleukins and integrins. We conclude that observed anti-tumour response and metastasis suppression of B16-F10/TIMP-2
tumours may stem from mRNA expression up-regulation of pro-inflammatory genes.

Biography :

Emilia Grecka has completed her PhD in 2014 from Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology in Warsaw. She works as a
Postdoctoral Fellow in Department of Molecular and Translational Oncology in Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology in
Warsaw. She co-authored number of papers in domestic and international journals.